Cargando…
The Association between Patient Characteristics and the Efficacy and Safety of Selinexor in Diffuse Large B-Cell Lymphoma in the SADAL Study
SIMPLE SUMMARY: Diffuse large B-cell lymphoma (DLBCL) is a complex disease. A combination of immunotherapy and chemotherapy is used to treat DLBCL at initial diagnosis. Additional treatments are available when DLBCL does not respond to initial treatment; however, for many patients, DLBCL will stop r...
Autores principales: | Zijlstra, Josée M., Follows, George, Casasnovas, Rene-Olivier, Vermaat, Joost S. P., Kalakonda, Nagesh, Choquet, Sylvain, Hill, Brian, Thieblemont, Catherine, Cavallo, Federica, la Cruz, Fatima De, Kuruvilla, John, Hamad, Nada, Jaeger, Ulrich, Caimi, Paolo, Gurion, Ronit, Warzocha, Krzysztof, Bakhshi, Sameer, Sancho, Juan-Manuel, Schuster, Michael, Egyed, Miklos, Offner, Fritz, Vassilakopoulos, Theodoros P., Samal, Priyanka, Ku, Matthew, Xu, Jenny, Corona, Kelly, Chamoun, Kamal, Shah, Jatin, Canales, Miguel, Maerevoet, Marie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8834328/ https://www.ncbi.nlm.nih.gov/pubmed/35159058 http://dx.doi.org/10.3390/cancers14030791 |
Ejemplares similares
-
Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study
por: Maerevoet, Marie, et al.
Publicado: (2021) -
Selinexor for multiple myeloma
Publicado: (2022) -
Selinexor, daratumumab, and dexamethasone in patients with relapsed or refractory multiple myeloma
por: Gasparetto, Cristina, et al.
Publicado: (2020) -
Selinexor in relapsed/refractory multiple myeloma
por: Richter, Joshua, et al.
Publicado: (2020) -
Selinexor and COVID-19: The Neglected Warden
por: Mostafa-Hedeab, Gomaa, et al.
Publicado: (2022)